Apyx Medical Corp APYX.OQ APYX.O is expected to show a fall in quarterly revenue when it reports results on August 7 for the period ending June 30 2025
The Clearwater Florida-based company is expected to report a 3.7% decrease in revenue to $11.699 million from $12.15 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Apyx Medical Corp is for a loss of 9 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Apyx Medical Corp is $4.00, about 53.8% above its last closing price of $1.85
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.12
-0.12
-0.10
Beat
16.7
Dec. 31 2025
-0.17
-0.16
-0.12
Beat
25
Sep. 30 2024
-0.19
-0.19
-0.14
Beat
24.6
Jun. 30 2024
-0.20
-0.20
-0.19
Beat
4.1
Mar. 31 2024
-0.22
-0.21
-0.22
Missed
-2.6
Dec. 31 2023
-0.20
-0.18
-0.28
Missed
-57.7
Sep. 30 2023
-0.12
-0.11
-0.13
Missed
-14.8
Jun. 30 2023
-0.07
-0.07
-0.11
Missed
-58.5
This summary was machine generated August 5 at 21:31 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)